The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second primary malignances (SPMs) in patients with gastrointestinal stromal tumors (GIST): The potential influence of imatinib treatment.
Anna Estival
No relevant relationships to disclose
Laia Espasa
No relevant relationships to disclose
Olatz Etxaniz
No relevant relationships to disclose
Ignacio Blanco
No relevant relationships to disclose
Jose Luis Cuadra-Urteaga
No relevant relationships to disclose
Maria de los Llanos Gil
No relevant relationships to disclose
Carmen Balana
No relevant relationships to disclose
Isabel Ojanguren
No relevant relationships to disclose
Alberto Indacochea
No relevant relationships to disclose
Sara Ahlal
No relevant relationships to disclose
Laia Vila
No relevant relationships to disclose
Enric Carcereny
No relevant relationships to disclose
Erika Mijangos
No relevant relationships to disclose